Market closed · data as of 27 Aug 2026 · source NSE via Alphave. Open the live chart →
Ipca Laboratories is a pharmaceutical company manufacturing branded and generic formulations and active pharmaceutical ingredients (APIs). Its domestic branded business is strong in pain management (Zerodol franchise), rheumatology, anti-malarials and cardiovascular therapies; it is a leading global producer of APIs such as hydroxychloroquine and artemisinin-based anti-malarials. It acquired control of Unichem Laboratories to expand US generics exposure. Revenue is driven by India branded formulations, export formulations and APIs.
It is a top-20 Indian pharma company by domestic sales with global leadership in select APIs like hydroxychloroquine.
Ipca Laboratories Ltd. is a constituent of NIFTY 500, NIFTY HEALTHCARE, NIFTY MIDCAP 150, NIFTY PHARMA. See where it sits on the market heatmap →
Consolidated annual figures taken from Ipca Laboratories Ltd.'s own filed statements — not estimates, and not restated by us. The most recent period shown is FY26 (year ended 31 Mar 2026).
| Metric | FY26 | FY25 | FY24 |
|---|---|---|---|
| EPS (basic, ₹) | 44.98 | 29.08 | 21.57 |
| Book value / share (₹) | 375.41 | 330.64 | 304.57 |
| Return on equity | 12.0% | 8.8% | 7.1% |
| Return on capital employed | 15.5% | 14.2% | 11.0% |
| Operating margin | 16.2% | 14.9% | 12.5% |
| Net margin | 12.3% | 8.8% | 6.8% |
| EBITDA | ₹1,979 Cr | ₹1,726 Cr | ₹1,321 Cr |
| Free cash flow | ₹490 Cr | ₹546 Cr | ₹533 Cr |
| Total debt | ₹704 Cr | ₹1,302 Cr | ₹1,388 Cr |
| Debt to equity | 0.07 | 0.16 | 0.18 |
| Interest coverage | 20.6 | 15.6 | 7.0 |
| Current ratio | 2.76 | 2.50 | 2.35 |
| Shares outstanding | 25,37,00,000 | 25,37,00,000 | 25,37,00,000 |
Open the full income statement, balance sheet and cash flow for IPCALAB →
As disclosed for the quarter ended 30 Jun 2026.
Institutional ownership changes quarter to quarter. See daily FII and DII flows across the market →
Companies Alphave classifies in the same sub-sector, closest by market capitalisation.